---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-117689"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T19:28:03.203925+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BrainStorm Q3 net loss $6.9M; FDA refuses to file NurOwn BLA for ALS

## Summary
- Cash & short-term deposits $7.4M as of Sep 30, down from $12.2M on Jun 30.
- Net loss $6.9M in Q3 2022 vs $5.3M in Q3 2021; EPS -$0.19 vs -$0.15.
- FDA refused to file new BLA for NurOwn in ALS; company plans to request Type A meeting.
- Phase 3 ALS post-hoc analyses at NEALS meeting addressed ALSFRS-R floor effect.
- Phase 2 progressive MS trial results published showing safety and preliminary efficacy.

## SEC filing metadata
- accession: 0001104659-22-117689
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465922117689/0001104659-22-117689-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465922117689/tm2230408d1_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-117689
- JSON: https://secwatch.observer/filing/0001104659-22-117689.json
- Plain text: https://secwatch.observer/filing/0001104659-22-117689.txt

## Key facts
- Earnings Releases
  BRAINSTORM CELL THERAPEUTICS INC. reported the third quarter ended September 30, 2022 results: net income Net loss for the three months ended September 30, 2022, was approximately $6.9 million, EPS Net loss per share for the three months ended September 30, 2022, and 2021 was $0.19.
  - Period: the third quarter ended September 30, 2022
  - Net income: Net loss for the three months ended September 30, 2022, was approximately $6.9 million
  - EPS: Net loss per share for the three months ended September 30, 2022, and 2021 was $0.19
  - Result: reported results
  source text: Net loss for the three months ended September 30, 2022, was approximately $6.9 million, as compared to a net loss of approximately $5.3 million for the three months ended September 30, 2021. Net loss per share for the three months ended September 30, 2022, and 2021 was $0.19 and $0.15, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465922117689/0001104659-22-117689-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.